Study of a new immunotherapy combo for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests if adding a new immunotherapy drug (QL1706) to standard chemotherapy works better than chemotherapy alone for triple-negative breast cancer that has returned or spread. This is for people who have already tried 1 or 2 other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer is triple-negative breast cancer (negative for HER2, ER, and PR) that cannot be removed with surgery.
- You have had 1 or 2 prior treatments for advanced breast cancer, or your cancer came back within 12 months after finishing adjuvant therapy.
- Your cancer has gotten worse during or after your last treatment.
- You have at least one tumor that can be measured on a CT or MRI scan.
- You are willing to provide a blood or tissue sample for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy before surgery for early-stage triple-negative breast cancer. It aims to see if the treatment shrinks the tumor enough to make surgery more effective.
This study is testing a new two-in-one immunotherapy drug (QL1706) for people with advanced cancers like lung, breast, colon, or liver cancer that have gotten worse after at least one prior treatment. It aims to see how well the drug works in real-world settings.
This trial tests a new immunotherapy drug (QL1706) for people with advanced endometrial cancer whose previous immunotherapy stopped working. It aims to see if this different approach can help when standard treatments have failed.
This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy for women with advanced or recurrent endometrial cancer that hasn't been treated yet. It may help shrink or control the cancer.
This trial tests a new immunotherapy drug (QL1706) combined with a short course of common chemotherapy (anthracyclines or taxanes) for people with early-stage triple-negative breast cancer. The goal is to see if this combination is safe and helps shrink the tumor before surgery.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
Hear when a new Triple Negative Breast Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.